Journal
INNATE INFLAMMATION AND STROKE
Volume 1207, Issue -, Pages 143-148Publisher
BLACKWELL PUBLISHING
DOI: 10.1111/j.1749-6632.2010.05761.x
Keywords
PMN leukocytes; ischemic stroke; inflammation; clinical studies; treatment
Categories
Funding
- NIH [NS 026945, NS 053716, NS 038710]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS053716, R37NS038710, R01NS038710, R01NS026945] Funding Source: NIH RePORTER
Ask authors/readers for more resources
In preparation for designing and undertaking trials of strategies that can modulate innate inflammation to improve outcomes of ischemic injury, consideration of approaches that have managed cellular inflammation in ischemic stroke are instructive. Robust experimental work has demonstrated the efficacy (and apparent safety) of targeting PMN leukocyte-endothelial cell interactions in the early moments following focal ischemia onset in model systems. Four clinical trial programs were undertaken to assess the safety and efficacy of inhibitors to PMN leukocyte interactions with the endothelial cell during ischemic stroke. Experiences in those clinical trial programs indicate specific limitations that halted progress in this line of investigation before an adequate hypothesis test could be achieved. Although innate inflammation is a central part of injury evolution following focal ischemia, great care in the translation from experimental studies to Phase I/II clinical safety assessments and to the design and conduct of Phase III trials is needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available